Regeneron (REGN) Reports REGN5678 Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Regeneron (REGN) Reports REGN5678 Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo

Oppenheimer Positive on Regeneron Pharma (REGN), 'We anticipate material pipeline readouts in 2H22/1H23'

August 4, 2022 10:21 AM EDT

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $775.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Regeneron (REGN) reported 2Q22 sales/earnings on 8/3 and provided a business update. Sales modestly outpaced OPCO expectations while earnings beat our estimates by... More